Compare WFC & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFC | MRK |
|---|---|---|
| Founded | 1852 | 2000 |
| Country | United States | United States |
| Employees | 205000 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.0B | 268.7B |
| IPO Year | N/A | 1994 |
| Metric | WFC | MRK |
|---|---|---|
| Price | $79.40 | $111.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 17 |
| Target Price | $96.59 | ★ $125.59 |
| AVG Volume (30 Days) | ★ 12.9M | 7.3M |
| Earning Date | 04-14-2026 | 04-30-2026 |
| Dividend Yield | 2.24% | ★ 2.97% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $11.08 | $3.61 |
| Revenue Next Year | $4.76 | $5.41 |
| P/E Ratio | ★ $14.15 | $15.78 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $68.67 | $75.40 |
| 52 Week High | $97.76 | $125.14 |
| Indicator | WFC | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 37.97 |
| Support Level | $77.23 | $105.23 |
| Resistance Level | $79.72 | $112.44 |
| Average True Range (ATR) | 1.66 | 2.99 |
| MACD | -0.24 | -0.95 |
| Stochastic Oscillator | 2.15 | 2.80 |
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).